High materiality8/10
BLTE price target raised to $206 from $201 at Morgan Stanley
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley lifts Belite Bio target to 206; current price is 164.01, implying meaningful upside ahead.
- Target raised to 206; price 164.01
- Upside remains substantial
Key facts
- 01
Target: $206
- 02
Posted price: $164.01
- 03
Analyst firm: Morgan Stanley
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.